This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...

Stock futures dipped early Friday morning as investors geared up to closely monitor new personal spending and inflation data. These economic indicators could of ...

The US FDA has approved Bristol Myers Squibb’s oral medicine, Cobenfy, for treating schizophrenia in adults. This is the ...

Shares jumped 6% in premarket trading after the Food and Drug Administration approved a treatment for [schizophrenia patients]( ...

Bristol-Myers Squibb shares rose in premarket trade on Friday after the Food and Drug Administration approved a schizophrenia ...

This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...

Bristol Myers Squibb (BMY) announced that the U.S. Food and Drug Administration has approved COBENFY (xanomeline and trospium ...

The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia,  the FDA announced Thursday.

Bristol-Myers Squibb (BMY) stock rises as FDA approves Cobenfy as a ovel treatment for adults with the psychiatric disorder ...

Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...

The U.S. Food and Drug Administration has granted approval to Cobenfy, the first new schizophrenia drug in decades.

This drug takes the first new approach to schizophrenia treatment in decades," Farchione continued. "This approval offers a ...